Valneva (VLA) Company presentation summary

Strategic focus and vision

• Aims to eliminate suffering and death from vaccine-preventable diseases through innovative R&D and commercial growth.

• Focuses on proprietary travel vaccines and blockbuster clinical catalysts, notably VLA15 for Lyme disease.

• Leverages integrated biotech operations to accelerate development and enhance manufacturing and commercial capabilities.

• Plans to expand the R&D pipeline post-VLA15 and pursue strategic in-licensing and M&A.

• Maintains a strong ESG agenda, prioritizing universal access, environmental sustainability, and workforce diversity.

Commercial portfolio and market position

• Proprietary vaccines include IXIARO (Japanese encephalitis), DUKORAL (cholera/ETEC), and IXCHIQ (chikungunya), with direct and partner-driven market reach.

• IXCHIQ is a single-shot, live-attenuated chikungunya vaccine approved in multiple regions, targeting travelers, military, and outbreak preparedness.

• S4V2 is the most advanced tetravalent Shigella vaccine candidate, targeting travelers, military, and children in endemic countries.

• Commercial business is expected to remain cash-flow positive, with product sales guidance of €145–€160 million for 2026.

• Focus on direct sales of proprietary products and cost-efficient manufacturing to improve gross margins.

R&D pipeline and clinical milestones

• VLA15 is the only Lyme disease vaccine in advanced clinical development, partnered with Pfizer, with Phase 3 data readout expected in H1 2026.

• VLA15 demonstrated strong immunogenicity in adults and children, with a three-dose schedule selected for Phase 3.

• IXCHIQ is expanding its label and access, with ongoing post-marketing studies and a Phase 4 program supported by a CEPI grant.

• S4V2 Shigella vaccine is in Phase 2 studies, with infant and CHIM data expected in 2026; awarded FDA Fast Track designation.

• Pipeline includes early-stage candidates for EBV and enteric diseases, with a strategic focus on antimicrobial resistance.